X-Therma’s XT-ViVo® & TimeSeal® a next-generation organ preservation system, was featured as one of the 20 groundbreaking technologies presented at the event. The system, which enables ice-free organ preservation at subzero temperatures, was highlighted as a transformative solution that could significantly increase the availability of viable organs for transplantation, reduce the risk of organ rejection, and facilitate transplant donation and surgery operations.
The technology was presented by Dr. Gerald Brandacher, Dr. Byoung Chol Oh, and Amanda Loftin, PhD, DVM from Johns Hopkins University, with attendees including members of the U.S. Senate. XT-ViVo® and TimeSeal® was recognized as one of the 16 new discoveries that have the potential to save lives, further cementing X-Therma’s position as a leader in the field of sub-zero ice-free organ preservation.
A Leap Forward in Organ Transplantation
XT-ViVo® leverages X-Therma’s proprietary antifreeze peptoids, inspired by Arctic species, to prevent ice crystal formation during preservation. Combined with the smart transporter TimeSeal®, this innovative platform extends the viable preservation time of organs from hours to multiple days by enabling ice-free storage at sub-zero temperature, addressing one of the most critical challenges in organ transplantation: the limited time available to get a generously donated organ into a critically ill recipient. By enabling subzero temperature storage, X-Therma’s technology has the potential to significantly increase the number of organs available for transplant, reduce organ wastage, and facilitate global organ sharing.
“It was great to see the interest, hear extremely positive feedback, and feel the excitement about our technology on Capitol Hill!” said Dr. Gerald Brandacher, a key collaborator with X-Therma.
“We received much interest from attendees about the potential life-saving technology in the near future using XT-ViVo and TimeSeal for subzero organ storage,” added Dr. Byoung Chol Oh.
A Mission to Transform Organ Transplantation
X-Therma’s participation in Hopkins on the Hill underscores the company’s commitment to advancing organ preservation and transplantation. Supported by the NIH SBIR Direct-to-Phase II program, X-Therma’s work is a testament to the value of federally funded research in driving innovation that can save lives and improve healthcare outcomes.
“The strong engagement drawn from Capitol Hill highlights the power of science-driven collaboration to rapidly transform transplant care—from breakthrough innovation to the bedside. We are deeply grateful for our fruitful partnership with Dr. Gerald Brandacher and Dr. BC Ohat Johns Hopkins over the years,” commented Xiaoxi Wei, Co-Founder & CEO of X-Therma.
The company’s technology has already achieved significant milestones, including the World’s first, and continued, successful transatlantic transport of pig kidneys ranging between 48 hours to 72 hours using the FDA Breakthrough-Designated preservation system – XT-ViVo® and TimeSeal®. With the ability to be carried on a commercial aircraft, TimeSeal® allows for precise monitoring of temperature, storage duration, and location without requiring external power, blood, or oxygen.
This world-first achievement demonstrates the potential of X-Therma’s solutions to extend organ preservation times and eventually enable global organ sharing, once United States organ transplant needs are met.
About X-Therma Inc.
X-Therma Inc., headquartered in Hercules, California, is a leading biotechnology company dedicated to revolutionizing regenerative medicine and organ transplantation. Drawing inspiration from nature, X-Therma has developed a scalable, non-toxic, and biocompatible antifreeze molecule that prevents ice crystal formation during preservation. The company’s core offerings, including XT-Thrive®, XT-ViVo®, and TimeSeal®, are designed to extend the reach of regenerative medicines e.g. cell and gene therapies, tissue engineering and organ transplants, enabling ultra-long preservation and global organ sharing.
With an expanding presence in Austria and recent oversubscribed Series B funding of $22.4 million, X-Therma is poised to accelerate the commercialization and clinical development of its groundbreaking technologies. In 2022, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device status to XT-ViVo® and TimeSeal® for human kidney preservation up to 120 hours for transplant.
The company’s FDA Breakthrough-Designated preservation system is already transforming the field of organ preservation, offering hope to millions of patients awaiting life-saving transplants.
Looking Ahead
X-Therma’s participation in Hopkins on the Hill marks a significant step forward in the company’s mission to transform organ transplantation. As the demand for viable organs continues to grow, X-Therma’s innovative solutions are poised to play a pivotal role in addressing this critical global healthcare challenge.
For more information about X-Therma and its groundbreaking technologies, visit www.x-therma.com.
Media Contact: [email protected] Investor Relations:[email protected] Information about XT-ViVo® and TimeSeal®: jsneve@x-therma.com
This press release is a testament to X-Therma’s commitment to innovation and its role as a leader in the field of organ cryopreservation. The company’s participation in Hopkins on the Hill highlights the transformative potential of its technology and its ability to save lives on a global scale.
SOURCE X-Therma Inc.
